BioCentury
ARTICLE | Finance

B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up

Engineered B cell platform company Be Bio moves autologous therapies toward clinic, attracts Arch with allogeneic strategy 

April 14, 2022 10:12 PM UTC

Although Be Bio isn’t yet disclosing any details of its nascent pipeline programs, the engineered B cell therapy developer intends to use its new $130 million series B round to beef up ...



Access this Article